Avon looks into allegations in China
This article was originally published in The Rose Sheet
Executive Summary
Avon notifies Securities and Exchange Commission and U.S. Department of Justice that it is conducting voluntary internal investigation of its China operations, under the oversight of its Audit Committee, with focus on compliance with Foreign Corrupt Practices Act, according to Oct. 20 release. Investigation launched in June following receipt of allegation that "certain travel, entertainment and other expenses may have been improperly incurred in connection with the company's China operations," firm says. "Investigation is in its early stage, and no conclusion can be drawn at this time as to its outcome," says Avon
You may also be interested in...
Avon Suspends Four Execs As Investigation Goes On Into Bribery Allegations
Avon has suspended four of its executives - three with ties to its operations in China, as well as the company's VP-global finance - in connection with an internal investigation into alleged violations of the U.S. Foreign Corrupt Practices Act
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.